Carisma Therapeutics, Inc. (CARM)

NASDAQ: CARM · IEX Real-Time Price · USD
1.120
+0.100 (9.80%)
At close: Jun 24, 2024, 4:00 PM
1.041
-0.079 (-7.05%)
After-hours: Jun 24, 2024, 5:42 PM EDT
9.80%
Market Cap 46.53M
Revenue (ttm) 15.07M
Net Income (ttm) -81.22M
Shares Out 41.54M
EPS (ttm) -1.96
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 150,143
Open 1.020
Previous Close 1.020
Day's Range 1.000 - 1.130
52-Week Range 0.990 - 9.766
Beta n/a
Analysts Strong Buy
Price Target 9.20 (+721.43%)
Earnings Date Aug 8, 2024

About CARM

Carisma Therapeutics, Inc., a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, inc... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2016
Employees 107
Stock Exchange NASDAQ
Ticker Symbol CARM
Full Company Profile

Financial Performance

In 2023, CARM's revenue was $14.92 million, an increase of 51.71% compared to the previous year's $9.83 million. Losses were -$86.88 million, 41.9% more than in 2022.

Financial Statements

Analyst Forecast

According to 5 analysts, the average rating for CARM stock is "Strong Buy." The 12-month stock price forecast is $9.2, which is an increase of 721.43% from the latest price.

Price Target
$9.2
(721.43% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Carisma Therapeutics Announces Adjournment of Annual Meeting of Stockholders

Meeting will be reconvened on Friday, June 14, 2024 at 10:00 a.m. Eastern Time  PHILADELPHIA , June 13, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a cl...

11 days ago - PRNewsWire

Carisma Therapeutics to Participate in the Jefferies Global Healthcare Conference

PHILADELPHIA , May 30, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing inno...

25 days ago - PRNewsWire

Carisma Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of CT-0525, a Novel HER2-Targeting CAR-Monocyte

CT-0525 is the first CAR-Monocyte to be evaluated in humans in the solid tumor setting Initial data expected by year-end 2024 PHILADELPHIA , May 16, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nas...

5 weeks ago - PRNewsWire

Carisma Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

Announced CT-0525 as lead product candidate for anti-HER2 program; initial data expected by year-end 2024 Presented preclinical proof of concept data in liver fibrosis at ASGCT; expects to nominate a ...

6 weeks ago - PRNewsWire

Carisma Therapeutics Presents Preclinical Proof of Concept Data Demonstrating the Anti-Fibrotic Potential of Engineered Macrophages at ASGCT 2024

Novel anti-fibrotic engineered macrophage therapy reduced liver fibrosis in preclinical models Development candidate nomination expected in the first quarter of 2025 PHILADELPHIA , May 8, 2024 /PRNews...

6 weeks ago - PRNewsWire

Carisma Therapeutics to Participate in The Citizens JMP Life Sciences Conference

PHILADELPHIA , May 6, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innov...

7 weeks ago - PRNewsWire

Carisma Therapeutics Appoints Dr. Eugene P. Kennedy as Chief Medical Officer

Industry veteran with expertise in oncology and immuno-oncology and a strong track record of advancing programs through clinical development PHILADELPHIA , May 2, 2024 /PRNewswire/ -- Carisma Therapeu...

7 weeks ago - PRNewsWire

Carisma Therapeutics to Present New Data at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

Preclinical data highlights the potential of engineered macrophage cell therapy as a treatment for liver and lung fibrosis Novel Redirected Soluble Modulator technology has demonstrated the potential ...

2 months ago - PRNewsWire

Carisma Therapeutics to Present at Upcoming Conferences

PHILADELPHIA , April 3, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing inn...

2 months ago - PRNewsWire

Carisma Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

Company to prioritize CT-0525 as its anti-HER2 CAR-M product candidate and will cease further development of CT-0508 Other prioritized pipeline programs include the Company's in vivo CAR-M collaborati...

3 months ago - PRNewsWire

Carisma Therapeutics Announces Changes to its Board of Directors

Appointment of John Hohneker, M.D. Resignation of Chidozie Ugwumba PHILADELPHIA , April 1, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage ...

3 months ago - PRNewsWire

Carisma Announces Upcoming Presentations at the American Association for Cancer Research (AACR) Annual Meeting

PHILADELPHIA , March 21, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing in...

3 months ago - PRNewsWire

Carisma Therapeutics to Participate in TD Cowen's 44th Annual Health Care Conference

PHILADELPHIA , Feb. 28, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing inn...

4 months ago - PRNewsWire

Carisma Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

PHILADELPHIA , Dec. 21, 2023 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing inn...

6 months ago - PRNewsWire

First In Vivo CAR-M Lead Candidate Nominated Under Carisma-Moderna Collaboration

First lead candidate to address a solid tumor indication with significant unmet medical need Supportive pre-clinical proof of concept data reported at SITC 2023 that demonstrated feasibility, tolerabi...

Other symbols: MRNA
6 months ago - PRNewsWire

Carisma Therapeutics Announces FDA Clearance of IND Application for CT-0525, a Novel HER2-Targeting CAR-Monocyte

CT-0525 is the first CAR-Monocyte to be evaluated in humans in the solid tumor setting First patient expected to be treated in the first half of 2024 PHILADELPHIA , Nov. 28, 2023 /PRNewswire/ -- Caris...

7 months ago - PRNewsWire

Carisma Therapeutics to Participate in Evercore ISI HealthCONx Conference

PHILADELPHIA , Nov. 22, 2023 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing inn...

7 months ago - PRNewsWire

Carisma Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights

Presented updated data from Phase 1 clinical trial of CT-0508 at CAR-TCR Summit, further supporting CAR-M safety, feasibility and mechanism of action Selected clinical candidate for CT-1119, an anti-m...

8 months ago - PRNewsWire

Carisma Presents Pre-Clinical Proof of Concept for in vivo CAR-M using mRNA platform in collaboration with Moderna at SITC

- Data demonstrate feasibility, tolerability, and early efficacy of mRNA/LNP in vivo CAR-M therapy in pre-clinical models of metastatic solid tumors - Proof of concept achieved for platform under the ...

8 months ago - PRNewsWire

Carisma to Present First Results From in vivo CAR-M Collaboration with Moderna at SITC 2023

-Late-breaking abstract to be presented on November 3 rd at 11:30 am PT highlighting pre-clinical data with Moderna -Two additional pre-clinical data abstracts highlighting next-generation enhancement...

8 months ago - PRNewsWire

Carisma Therapeutics to Present at Upcoming Investor Conferences

PHILADELPHIA , Sept. 5, 2023 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing inn...

10 months ago - PRNewsWire

Carisma Announces Latest Data from Phase 1 Clinical Trial of CT-0508 at 8th Annual CAR-TCR Summit

Group 2 data available to date support primary safety and feasibility endpoints of single-day bolus dosing of CT-0508   New translational analyses combining group 1 & group 2 continue to support CAR-M...

10 months ago - PRNewsWire

Carisma Therapeutics to Present at Upcoming Healthcare Industry Conferences in September 2023

PHILADELPHIA , Aug. 24, 2023 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical stage biopharmaceutical company focused on discovering and developing inn...

10 months ago - PRNewsWire

Carisma Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights

Dosed first patient in Phase 1 clinical trial of CT-0508 in combination with KEYTRUDA® (pembrolizumab) in patients with HER2-overexpressing solid tumors Nominated additional oncology target as part of...

11 months ago - PRNewsWire

Carisma Therapeutics Announces First Patient Dosed in Phase 1 Study of CT-0508 in Combination with KEYTRUDA® (pembrolizumab) in Patients with HER2 Overexpressing Solid Tumors

Study is designed to evaluate the potential for a synergistic effect of CAR-M therapy in combination with KEYTRUDA® PHILADELPHIA , June 28, 2023 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM...

1 year ago - PRNewsWire